Incyte Corporation Closes Recruitment For NX-1207 Phase 2 Prostate Cancer Trial
Published: Jan 13, 2014
HASBROUCK HEIGHTS, N.J., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Help employers find you! Check out all the jobs and post your resume.